Mike Ralston, CEO of Blencowe Resources, explains the significance of the MSP for Orom-Cross. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksGenincode Regulatory News (GENI)

Share Price Information for Genincode (GENI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.25
Prev. Close: 5.25

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

13 Sep 2023 07:00

RNS Number : 2091M
GENinCode PLC
13 September 2023
 

GENinCode Plc

("GENinCode" or the "Company")

 

Notice of results

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces that it will release its unaudited interim results for the six months ended 30 June 2023 on Wednesday, 20 September 2023.

 

Investor presentation

Matthew Walls, Chief Executive Officer, and Paul Foulger, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on 20 September 2023 at 16:30 BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet GENinCode here. Investors who already follow GENinCode on the Investor Meet Company platform will automatically be invited.

 

For more information visit www.genincode.com

 

Enquiries:

 

GENinCode Plc

www.genincode.com or via Walbrook PR

Matthew Walls, CEO

Paul Foulger, CFO

 

Stifel Nicolaus Europe Limited (Nomad and Joint Broker)

Tel: +44 (0)20 7710 7600

Alex Price / Ben Maddison / Richard Short

 

Cavendish Capital Markets Ltd (Joint Broker)

Tel: +44 (0)20 7397 8900

Giles Balleny

Dale Bellis / Michael Johnson (Sales)

Walbrook PR Limited

Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

Tel: 020 7933 8780 or genincode@walbrookpr.com  

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict the onset of cardiovascular disease.

 

About Cardiovascular Disease (CVD):

 

CVD is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

 

CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas with the NHS 10 Year Plan identifying CVD as the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.

 

Early detection and treatment of CVD can help patients live longer, healthier lives. Too many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). The NHS 10 Year Plan is working towards people knowing and managing risks around their 'ABC' (AF, Blood pressure and Cholesterol).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORLTMATMTTBBTJ
12
Date   Source Headline
3rd May 20227:00 amRNSNotice of Results
6th Apr 20227:00 amRNSDirector Appointment
23rd Mar 20227:00 amRNSIndiana University Medical School collaboration
15th Mar 20227:00 amRNSLipid inCode pilot
21st Feb 20221:17 pmRNSConfirmation of board appointment
8th Feb 20227:00 amRNSPositive results for Lipid inCode in NHS study
21st Jan 20227:00 amRNSProposed independent directorate appointment
10th Jan 20227:00 amRNSFDA Pre-Submission for Cardio inCode-SCORE
29th Nov 20217:00 amRNSDirectorate Change
25th Nov 20217:00 amRNSTrading update
17th Sep 202110:38 amRNSGrant of Share Options and PDMR dealing
16th Sep 20217:00 amRNSHalf-year Report
2nd Sep 20217:00 amRNSNotice of Results
27th Jul 20219:27 amRNSHolding(s) in Company
26th Jul 20217:00 amRNSPositive Thrombo inCode clinical results
23rd Jul 20214:04 pmRNSHolding(s) in Company
23rd Jul 20219:53 amRNSHolding(s) in Company
22nd Jul 20217:00 amRNSAdmission to trading on AIM & First Day of Dealing
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Make Better Investment Decisions

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.